Sentiment-Signal
12,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | by reference. (e) The information provided in Item 5.02(b) of this Current Report on Form 8-K is incorporated by referen |
Stammdaten
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Unternehmen & Branche
| Name | Mirum Pharmaceuticals, Inc. |
|---|---|
| Ticker | MIRM |
| CIK | 0001759425 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,71 Mrd. USD |
| Beta | 0,52 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 521,312,000 | -23,363,000 | -0.47 | 842,813,000 | 314,690,000 |
| 2025-09-30 | 10-Q | 133,010,000 | 2,905,000 | 0.05 | 785,115,000 | 292,046,000 |
| 2025-06-30 | 10-Q | 127,785,000 | -5,861,000 | -0.12 | 725,825,000 | 255,158,000 |
| 2025-03-31 | 10-Q | 111,585,000 | -14,677,000 | -0.30 | 690,245,000 | 233,256,000 |
| 2024-12-31 | 10-K | 336,888,000 | -87,942,000 | -1.85 | 670,754,000 | 225,640,000 |
| 2024-09-30 | 10-Q | 90,377,000 | -14,235,000 | -0.30 | 667,893,000 | 232,024,000 |
| 2024-06-30 | 10-Q | 77,875,000 | -24,638,000 | -0.52 | 660,754,000 | 228,988,000 |
| 2024-03-31 | 10-Q | 69,222,000 | -25,279,000 | -0.54 | 651,962,000 | 234,603,000 |
| 2023-12-31 | 10-K | 186,374,000 | -163,415,000 | -4.00 | 646,621,000 | 248,670,000 |
| 2023-09-30 | 10-Q | 47,725,000 | -23,588,000 | -0.57 | 650,642,000 | 269,081,000 |
| 2023-06-30 | 10-Q | 37,497,000 | -74,038,000 | -1.94 | 443,588,000 | 78,610,000 |
| 2023-03-31 | 10-Q | 31,598,000 | -30,130,000 | -0.80 | 333,530,000 | 141,150,000 |
| 2022-12-31 | 10-K | 77,062,000 | -135,665,000 | -4.02 | 352,906,000 | 142,037,000 |
| 2022-09-30 | 10-Q | 18,780,000 | -35,706,000 | -1.02 | 364,347,000 | 169,297,000 |
| 2022-06-30 | 10-Q | 17,484,000 | -26,922,000 | -0.84 | 297,233,000 | 110,687,000 |
| 2022-03-31 | 10-Q | 12,892,000 | -36,606,000 | -1.17 | 278,148,000 | 108,932,000 |
| 2021-12-31 | 10-K | 19,138,000 | -83,988,000 | -2.77 | 294,651,000 | 120,212,000 |
| 2021-09-30 | 10-Q | 5,000,000 | -47,108,000 | -1.55 | 235,167,000 | 56,396,000 |
| 2021-06-30 | 10-Q | 11,000,000 | -43,894,000 | -1.45 | 247,668,000 | 95,737,000 |
| 2021-03-31 | 10-Q | 0 | -50,532,000 | 222,241,000 | 133,883,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Ramasastry Saira | Director | Open Market Sale | -2,000 | 96.90 | -193,800.00 | -20,0% | |
| 2026-03-16 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -4,732 | 91.98 | -435,239.42 | -45,0% | |
| 2026-03-16 | Ramasastry Saira | Director | Open Market Sale | -2,000 | 90.76 | -181,520.00 | -18,7% | |
| 2026-03-16 | Quan Joanne | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -7,287 | 91.98 | -670,242.96 | -69,2% | |
| 2026-03-16 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7,287 | 91.98 | -670,242.96 | -69,2% | |
| 2026-03-16 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -40,985 | 91.98 | -3,769,714.23 | -389,4% | |
| 2026-03-16 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -16,515 | 91.98 | -1,519,015.02 | -156,9% | |
| 2026-02-13 | Ramasastry Saira | Director | Open Market Sale | -2,000 | 102.09 | -204,180.00 | -21,1% | |
| 2026-02-02 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -2,631 | 103.30 | -271,791.51 | -28,1% | |
| 2026-02-02 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -9,108 | 103.30 | -940,888.28 | -97,2% | |
| 2026-02-02 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -968 | 103.30 | -99,997.79 | -10,3% | |
| 2026-01-26 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -842 | 96.19 | -80,993.66 | -8,4% | |
| 2026-01-26 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1,053 | 96.19 | -101,290.18 | -10,5% | |
| 2026-01-26 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -3,143 | 96.19 | -302,331.46 | -31,2% | |
| 2026-01-26 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -6,831 | 96.19 | -657,087.55 | -67,9% | |
| 2026-01-23 | Heron Patrick J | Director | Open Market Purchase | 131,425 | 68.48 | 8,999,984.00 | +929,6% | |
| 2026-01-22 | Quan Joanne | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,822 | 93.33 | -170,038.51 | -17,6% | |
| 2026-01-22 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1,421 | 93.33 | -132,615.11 | -13,7% | |
| 2026-01-22 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -926 | 93.33 | -86,419.14 | -8,9% | |
| 2026-01-22 | Radovich Peter | Officer, PRESIDENT AND COO | Open Market Sale | -2,382 | 93.33 | -222,300.63 | -23,0% | |
| 2026-01-22 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,098 | 93.33 | -662,422.27 | -68,4% | |
| 2026-01-20 | Quan Joanne | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -6,911 | 90.27 | -623,853.21 | -64,4% | |
| 2026-01-15 | Ramasastry Saira | Director | Open Market Sale | -2,000 | 90.99 | -181,980.00 | -18,8% | |
| 2025-12-22 | Ramasastry Saira | Director | Open Market Sale | -5,000 | 80.00 | -400,000.00 | -41,3% | |
| 2025-12-19 | GREY MICHAEL G | Director | Open Market Sale | -50,000 | 78.00 | -3,900,000.00 | -402,8% | |
| 2025-12-18 | Ramasastry Saira | Director | Open Market Sale | -1,000 | 70.00 | -70,000.00 | -7,2% | |
| 2025-12-18 | Ramasastry Saira | Director | Open Market Sale | -1,000 | 69.46 | -69,460.00 | -7,2% | |
| 2025-12-01 | GREY MICHAEL G | Director | Open Market Sale | -50,000 | 74.00 | -3,700,000.00 | -382,2% | |
| 2025-11-21 | GREY MICHAEL G | Director | Open Market Sale | -50,000 | 70.00 | -3,500,000.00 | -361,5% | |
| 2025-09-12 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -9,578 | 76.01 | -728,023.78 | -75,2% | |
| 2025-09-11 | Brege Laura | Director | Open Market Sale | -1,491 | 75.07 | -111,929.37 | -11,6% | |
| 2025-09-11 | Brege Laura | Director | Open Market Sale | -15,509 | 74.34 | -1,152,939.06 | -119,1% | |
| 2025-09-08 | Ramasastry Saira | Director | Open Market Sale | -17,000 | 0.00 | 0.00 | 0,0% | |
| 2025-08-11 | BJERKHOLT ERIC | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -8,000 | 0.00 | 0.00 | 0,0% | |
| 2025-08-11 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -40,000 | 62.00 | -2,480,000.00 | -256,1% | |
| 2025-08-07 | Peetz Christopher | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -40,000 | 55.25 | -2,210,040.00 | -228,3% | |
| 2025-08-07 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -10,000 | 58.00 | -580,000.00 | -59,9% | |
| 2025-07-03 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -477 | 49.08 | -23,411.16 | -2,4% | |
| 2025-07-02 | Howe Jolanda | Officer, SVP, GLOBAL CONTROLLER | Open Market Sale | -564 | 48.25 | -27,213.00 | -2,8% | |
| 2025-06-11 | Fairey William | Director | Open Market Sale | -3,203 | 48.42 | -155,090.54 | -16,0% | |
| 2025-06-03 | Ramasastry Saira | Director | Open Market Sale | -2,500 | 45.74 | -114,351.75 | -11,8% | |
| 2025-06-02 | Ramasastry Saira | Director | Open Market Sale | -5,703 | 46.20 | -263,491.72 | -27,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.